查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006246

支氣管擴張治療市場：2026-2032年全球市場預測（依藥物類型、給藥途徑、病患族群、支氣管擴張類型及分銷管道分類）

Bronchiectasis Drugs Market by Drug Type, Route Of Administration, Patient Demographics, Bronchiectasis Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年支氣管擴張治療市場價值 16.5 億美元，預計到 2026 年將成長至 18 億美元，複合年成長率為 9.55%，到 2032 年將達到 31.3 億美元。

主要市場統計數據
基準年 2025 16.5億美元
預計年份：2026年 18億美元
預測年份 2032 31.3億美元
複合年成長率 (%) 9.55%

對支氣管擴張藥物治療的進展、臨床重點以及不斷發展的治療創新框架進行了簡明扼要且權威的概述。

支氣管擴張症已從臨床實踐中鮮少受到關注的疾病，轉變為藥物研發的重點，這得益於診斷準確性的提高、治療假設的拓展以及對生活品質（QOL）日益重視。近年來，影像學、痰液微生物學和縱向患者登記技術的進步，促使研究方向趨於融合，涵蓋抗發炎策略、標靶抗菌療法、氣道清除方法以及支氣管擴張症的症狀治療。這種臨床見解與轉化科學的融合，使臨床醫生和相關人員不再將支氣管擴張症視為一種不可避免的疾病進展，而是將其視為一種可治療的慢性疾病。

深刻洞察標靶免疫調節、個人化治療和給藥方式的創新如何重塑支氣管擴張的治療模式。

支氣管擴張的治療格局正在經歷一場變革性的轉變，其驅動力包括靶向免疫調節、精準抗生素管理以及吸入系統的創新。首先，超越廣泛使用糖皮質激素的抗發炎策略的出現——包括選擇性通路調變器和佐劑——重塑了治療模式，優先控制慢性炎症，同時避免不可接受的全身暴露。這一轉變，加上對氣道微生物組動態的更深入理解，正在推動旨在降低病原體負荷並維持微生物生態系統的抗生素和生物製藥的研發。

對近期美國關稅趨勢如何推動呼吸系統治療藥物供應鏈的韌性、採購調整和籌資策略轉變進行實際分析。

美國近期關稅政策的變化為呼吸系統藥物的跨境供應鏈和採購計畫帶來了新的不穩定性。儘管關稅在不同產品類別和原料類別中的適用程度不一，但它們會影響活性成分、輔料、成品和專用給藥裝置的採購決策。實際上，製造商和經銷商正在重新審視供應商多元化、客戶合約條款和接收成本模型，以維持供應的連續性和可預測的商業環境。

將治療領域、給藥途徑、患者人口統計特徵、疾病病理生理學和分銷管道與策略決策聯繫起來的綜合細分框架。

精細的細分觀點將藥物特性、患者需求和通路相結合，從而明確支氣管擴張症領域的治療和商業策略。依藥物類型分類，抗發炎藥物（包括皮質類固醇和非類固醇消炎劑）主要針對慢性發炎環境，而抗生素則著重於抑制病原體和控制感染。支氣管擴張劑分為長效和短效兩種類型，以滿足維持治療和緊急治療的需求，祛痰藥則針對痰液黏稠度和排放機制。這種藥理學分類有助於產品定位、處方集討論和聯合治療決策。

從策略區域觀點探討醫療保健系統、法規結構和醫療保健服務生態系統如何影響全球市場支氣管擴張治療的取得和分配。

地理因素影響支氣管擴張治療的臨床可近性、監管預期和商業化模式。在美洲，醫療保健系統呈現出一種混合模式，以醫院主導監護和不斷擴展的門診服務為特色，並高度重視真實世界數據（REW）的生成以及與不同相關人員和支付方的互動。區域臨床網路和病患登記系統支援長期療效追蹤和可操作性研究，這些研究構成了醫保報銷和指引制定的基礎。

對支氣管擴張治療生態系中的主要企業進行詳細的競爭定位、創新路徑和合作模式分析。

支氣管擴張治療市場的競爭格局呈現出多元化的態勢，既有經驗豐富的呼吸專科醫生，也有專注於生物技術的專業公司，還有大規模多元化製藥企業。主要參與者通常透過專有的給藥平台、生物製藥或合理使用抗生素的策略來降低抗藥性風險，從而實現差異化競爭。有些機構優先考慮漸進式創新，將已知的活性成分重新包裝成吸入劑或長效製劑，以提高耐受性和患者依從性；而另一些機構則致力於First-in-Class的靶點，以調節參與粘液過度分泌和氣道重塑的特定炎症通路。

針對支氣管擴張症的治療經營團隊，提出切實有效的建議，旨在加速臨床應用，增強韌性，並為患者帶來可衡量的益處。

對於尋求持續差異化優勢和提升患者療效的行業領導者而言，一系列切實可行的方法可以加速臨床應用和商業性成功。首先，應優先產生能夠直接解決支付方和臨床醫生顧慮的證據：投資於臨床試驗和真實世界研究，以評估病情加重負擔、功能性結局和醫療資源利用情況，並以可靠的患者報告結局來補充臨床終點。其次，應最佳化給藥方式以減輕治療負擔：吸入製劑和易於使用的製劑能夠減少全身暴露，既符合臨床醫師的偏好，又能提高患者的依從性。

對混合方法研究途徑進行透明的解釋，該方法結合了臨床證據審查、監管分析、相關人員訪談和產品生命週期評估。

本研究採用混合方法，結合了臨床文獻評估、監管環境審查、相關人員訪談以及醫療設備和製劑發展趨勢分析。臨床文獻評估重點在於試驗設計要素、終點選擇以及各治療類別的安全性概況。監管指南和已發布的申報文件經過仔細審查，以確定不斷變化的核准標準和上市後證據要求。來自臨床醫生、藥物負責人和供應鏈專家的關鍵定性意見被用於解讀推廣應用障礙和營運限制。

一項權威的綜合分析強調了整合臨床、營運和商業策略的必要性，以實現支氣管擴張治療的治療價值。

維持支氣管擴張治療的良好勢頭需要一項整合策略，該策略應將科學創新、營運韌性和相關人員合作相結合。不斷湧現的實證依證支持向臨床差異化和方便用戶使用型治療方法轉變，而商業性成功則取決於靈活的分銷模式、引人入勝的支付方方案以及以患者為中心的療效的顯著改善。同樣重要的是，要能夠透過積極的規劃和夥伴關係來應對供應鏈波動、監管差異和不斷變化的臨床預期。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：支氣管擴張治療藥物市場（依藥物類型分類）

  • 抗發炎藥
    • 皮質類固醇
    • NSAIDs
  • 抗生素
  • 支氣管擴張劑
    • 長效支氣管擴張劑
    • 短效支氣管擴張劑
  • 祛痰藥

第9章：支氣管擴張治療市場：依給藥途徑分類

  • 吸入
  • 注射
    • 靜脈
    • 皮下
  • 口服

第10章：依患者細分分類的支氣管擴張治療市場

  • 成人版
  • 老年人
  • 兒童

第11章：以支氣管擴張類型分類的支氣管擴張治療市場

  • 圓柱形（管狀）
  • 類似靜脈曲張的（囊性）

第12章 支氣管擴張治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 支氣管擴張治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 支氣管擴張治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 支氣管擴張治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國支氣管擴張治療市場

第17章：中國支氣管擴張治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AdvaCare Pharma
  • Armata Pharmaceuticals
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Insmed Incorporated
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Renovion, Inc.
  • Sanofi SA
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Verona Pharma PLC
  • ZAMBON COMPANY SPA
  • Zydus Group
Product Code: MRR-B1685377A3D9

The Bronchiectasis Drugs Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.80 billion in 2026, with a CAGR of 9.55%, reaching USD 3.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.80 billion
Forecast Year [2032] USD 3.13 billion
CAGR (%) 9.55%

A concise and authoritative orientation to bronchiectasis pharmacotherapy developments, clinical priorities, and the evolving framework for therapeutic innovation

Bronchiectasis has emerged from clinical obscurity to become a focal point for drug development, driven by improved diagnostic recognition, expanding therapeutic hypotheses, and a growing emphasis on quality-of-life outcomes. Recent years have seen a convergence of research efforts across anti-inflammatory strategies, targeted antimicrobial approaches, airway clearance modalities, and symptomatic bronchodilation, all informed by advances in imaging, sputum microbiology, and longitudinal patient registries. This combination of clinical insight and translational science has reshaped how clinicians and industry stakeholders view the disease as a treatable chronic condition rather than an inevitably progressive one.

Consequently, pipelines now reflect a blend of repurposed agents, novel molecular entities, and delivery-optimized formulations intended to address the multifactorial pathophysiology of bronchiectasis. Regulatory dialogues increasingly emphasize patient-reported outcomes and exacerbation reduction as meaningful endpoints, while payers and providers focus on therapies that demonstrably reduce healthcare utilization and improve daily functioning. As a result, strategic decision-making requires an integrated view of clinical evidence, therapeutic differentiation, and practical adoption barriers to translate scientific advances into sustainable patient benefit.

An incisive account of how targeted immunomodulation, therapeutic personalization, and delivery innovation are reshaping treatment paradigms for bronchiectasis

The therapeutic landscape for bronchiectasis is undergoing transformative shifts driven by targeted immunomodulation, precision antimicrobial stewardship, and innovations in inhalation delivery systems. First, the emergence of anti-inflammatory strategies that extend beyond broad corticosteroid use-incorporating selective pathway modulators and adjunctive agents-has reframed treatment paradigms to prioritize chronic inflammation control without unacceptable systemic exposure. This shift is coupled with a more nuanced appreciation of airway microbiome dynamics, prompting development of antibiotics and biologics that aim to reduce pathogenic burden while preserving microbial ecology.

Concurrently, device- and formulation-driven advances have reduced the friction of long-term therapy, with inhaled formulations and optimized nebulizer technologies enabling higher local drug concentrations and improved tolerability. On the regulatory and evidence front, stakeholders now place greater weight on patient-centered endpoints, including exacerbation frequency, functional capacity, and health-related quality of life, which in turn influences trial design and postmarketing value demonstration. Taken together, these shifts are fostering a more patient-centric, precision-oriented approach to bronchiectasis management that aligns clinical objectives with product innovation and adoption pathways.

A pragmatic exploration of how recent United States tariff dynamics are prompting supply chain resilience, sourcing adjustments, and procurement strategy shifts in respiratory therapeutics

Recent tariff developments in the United States have introduced a new variable into cross-border supply chains and procurement planning for respiratory pharmaceuticals. While tariffs are applied unevenly across product classes and raw material categories, they can influence sourcing decisions for active pharmaceutical ingredients, excipients, finished dosage forms, and specialized delivery devices. In practice, manufacturers and distributors are reassessing supplier diversification, client contractual terms, and landed-cost models to maintain supply continuity and predictable commercial terms.

In response to tariff-induced cost pressure, several industry participants have either accelerated localization of manufacturing capacity, negotiated longer-term supply contracts with hedging provisions, or optimized product portfolios to prioritize formulations and packaging formats that are less exposed to incremental duties. Buyers and health systems, in turn, are revisiting tender structures and inventory strategies to mitigate short-term price volatility. Crucially, these operational adjustments emphasize resilience: supply chain visibility, alternative sourcing, and collaborative planning with logistics partners help ensure that patient access and therapeutic continuity remain intact despite tariff-related headwinds.

A comprehensive segmentation framework linking therapeutic class, administration route, patient cohorts, disease morphology, and distribution channels to strategic decision-making

A refined segmentation lens clarifies therapeutic and commercial strategies across the bronchiectasis landscape by aligning drug attributes, patient needs, and distribution pathways. When classifying by drug type, anti-inflammatory agents-including corticosteroids and nonsteroidal anti-inflammatory agents-address the chronic inflammatory milieu, while antibiotics concentrate on pathogen suppression and infection control; bronchodilators are differentiated into long-acting and short-acting agents to meet both maintenance and rescue needs, and mucolytics target sputum viscosity and clearance mechanics. This pharmacologic taxonomy informs product positioning, formulary discussions, and combination regimens.

Route of administration drives adherence and delivery considerations: inhalation approaches minimize systemic exposure and support home-based therapy, injection routes-comprising both intravenous and subcutaneous options-are reserved for severe exacerbations or biologic therapies, and oral therapies remain central for ease of use and outpatient management. Patient demographics further nuance clinical strategy, as adult, geriatric, and pediatric populations present differing comorbidity profiles, tolerability windows, and dosing requirements. Disease subtype stratification between cylindrical (tubular) and varicose (cystic) bronchiectasis contributes diagnostic and prognostic context that can influence therapeutic choice and trial cohort selection. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies defines access touchpoints, reimbursement workflows, and patient support program design, all of which are essential for achieving meaningful uptake and sustained adherence.

A strategic regional perspective on how healthcare systems, regulatory frameworks, and delivery ecosystems shape bronchiectasis therapy access and adoption across global markets

Geographic contours shape clinical access, regulatory expectations, and commercialization approaches for bronchiectasis therapies. In the Americas, healthcare systems demonstrate a mix of centralized hospital-led care and expanding outpatient services, with strong emphasis on real-world evidence generation and multi-stakeholder payer engagements. Clinical networks and patient registries in this region support longitudinal outcome tracking and pragmatic studies that inform reimbursement dossiers and guideline development.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse reimbursement environments necessitate adaptable clinical narratives and localized health economic arguments. In several jurisdictions, accelerated pathways for unmet-need respiratory therapies coexist with rigorous cost-effectiveness evaluation, requiring tailored evidence packages. In the Asia-Pacific region, heterogeneity in healthcare infrastructure, rapid adoption of inhalation technologies, and growing investment in local manufacturing capacity drive distinct commercialization strategies; partnerships with regional distributors and attention to cold-chain and logistics considerations can materially affect availability and uptake. Taken together, these regional differences underline the importance of flexible market entry plans and evidence generation strategies that reflect local payer priorities and clinical practice patterns.

An informed analysis of competitive positioning, innovation pathways, and collaborative models that define leading companies in the bronchiectasis therapeutics ecosystem

Competitive dynamics in bronchiectasis therapeutics reflect a mix of established respiratory specialists, specialty biotech firms, and larger diversified pharmaceutical companies. Key players often differentiate through proprietary delivery platforms, biologic modalities, or antimicrobial stewardship strategies that reduce resistance risk. Some organizations prioritize incremental innovation by reformulating known active molecules into inhaled or longer-acting forms, thereby improving tolerability and adherence, while others pursue first-in-class targets that modulate specific inflammatory pathways implicated in mucus hypersecretion and airway remodeling.

Collaboration is increasingly prominent, as clinical development often requires access to specialized registries, diagnostic capabilities, and patient support services. Partnerships between developers and contract manufacturing organizations enable flexible scale-up and localized production, and licensing agreements are used to accelerate geographic expansion. From a commercial perspective, market entrants that combine strong clinical differentiation with robust patient support and healthcare professional education programs are better positioned to secure formulary placement and clinical adoption. Moreover, organizations that invest in post-authorization evidence generation and digital adherence solutions tend to strengthen their long-term value propositions.

Practical, high-impact recommendations for leadership teams to accelerate clinical adoption, enhance resilience, and deliver measurable patient benefit in bronchiectasis care

For industry leaders seeking durable differentiation and patient impact, a set of pragmatic actions can accelerate clinical adoption and commercial success. First, prioritize evidence generation that directly addresses payer and clinician concerns: invest in trials and real-world studies that measure exacerbation burden, functional outcomes, and healthcare resource utilization, and complement clinical endpoints with robust patient-reported measures. Second, optimize delivery modalities to lower treatment burden; inhaled and user-friendly formulations that reduce systemic exposure will align with both clinician preference and patient adherence.

Next, strengthen supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory strategies that reduce vulnerability to tariff and logistics disruptions. Additionally, design distribution and patient support pathways that integrate hospital, retail, and digital pharmacy channels to maximize accessibility and continuity of care. Finally, invest in cross-functional stakeholder engagement-clinical champions, payer evidence teams, and patient advocacy groups-to create aligned value narratives that expedite inclusion in treatment protocols and formularies. These coordinated steps enhance the likelihood that therapeutic innovations translate into improved outcomes and sustained clinical uptake.

A transparent explanation of the mixed-methods research approach blending clinical evidence review, regulatory analysis, stakeholder interviews, and product lifecycle assessment

This research synthesis is grounded in a mixed-methods approach that combines clinical literature appraisal, regulatory landscape review, stakeholder interviews, and synthesis of device and formulation trends. Clinical literature was evaluated with attention to trial design elements, endpoint selection, and safety profiles across therapeutic classes. Regulatory guidance and public filings were examined to identify evolving approval criteria and postmarketing evidence expectations. Primary qualitative inputs from clinicians, formulary managers, and supply chain specialists informed interpretation of adoption barriers and operational constraints.

Complementing qualitative inputs, product and technology assessments focused on delivery systems, manufacturing dependencies, and cold-chain or handling requirements. Cross-validation techniques were used to reconcile disparate data points and ensure consistency of conclusions. Where applicable, sensitivity to regional regulatory and reimbursement variance was applied to refine strategic implications. This blended methodology provides a robust foundation for the insights and recommendations presented, emphasizing practical applicability for clinical development, commercialization, and operations teams.

A conclusive synthesis underscoring the need for integrated clinical, operational, and commercial strategies to realize therapeutic value in bronchiectasis care

Sustaining momentum in bronchiectasis therapeutics requires integrated strategies that bridge scientific innovation, operational resilience, and stakeholder alignment. The evolving evidence base supports a transition toward therapies that are both clinically differentiated and user-friendly, while commercial success will hinge on adaptable distribution models, compelling payer narratives, and demonstrable improvements in patient-centered outcomes. Equally important is the ability to navigate supply chain volatility, regulatory diversity, and shifting clinical expectations with proactive planning and partnership.

Ultimately, the most effective programs will align therapeutic design with real-world use, coupling clinical efficacy with mechanisms to support adherence, access, and long-term value demonstration. Organizations that embrace this holistic view-investing in targeted evidence, resilient operations, and sustained stakeholder engagement-will be best positioned to convert scientific advances into meaningful improvement in patient care and health system performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchiectasis Drugs Market, by Drug Type

  • 8.1. Anti-Inflammatory Agents
    • 8.1.1. Corticosteroids
    • 8.1.2. NSAIDs
  • 8.2. Antibiotics
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
    • 8.3.2. Short-Acting Bronchodilators
  • 8.4. Mucolytics

9. Bronchiectasis Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injection
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral

10. Bronchiectasis Drugs Market, by Patient Demographics

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Bronchiectasis Drugs Market, by Bronchiectasis Type

  • 11.1. Cylindrical (Tubular)
  • 11.2. Varicose (Cystic)

12. Bronchiectasis Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bronchiectasis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchiectasis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchiectasis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchiectasis Drugs Market

17. China Bronchiectasis Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AdvaCare Pharma
  • 18.6. Armata Pharmaceuticals
  • 18.7. AstraZeneca PLC
  • 18.8. Bayer AG
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Cipla Limited
  • 18.11. F. Hoffmann-La Roche AG
  • 18.12. GlaxoSmithKline PLC
  • 18.13. Glenmark Pharmaceuticals Limited
  • 18.14. Insmed Incorporated
  • 18.15. Lupin Limited
  • 18.16. Merck & Co., Inc.
  • 18.17. Mylan Inc. by Viatris Inc.
  • 18.18. Nephron Pharmaceuticals Corporation
  • 18.19. Novartis AG
  • 18.20. Perrigo Company PLC
  • 18.21. Pfizer Inc.
  • 18.22. Renovion, Inc.
  • 18.23. Sanofi S.A.
  • 18.24. Steris Healthcare Pvt. Ltd.
  • 18.25. Sun Pharmaceutical Industries Limited
  • 18.26. Teva Pharmaceutical Industries Ltd.
  • 18.27. Verona Pharma PLC
  • 18.28. ZAMBON COMPANY S.P.A.
  • 18.29. Zydus Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY LONG-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SHORT-ACTING BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY CYLINDRICAL (TUBULAR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY VARICOSE (CYSTIC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BRONCHIECTASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY BRONCHIECTASIS TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA BRONCHIECTASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)